Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of AZD5004 in Healthy Japanese and Type 2 Diabetes Participants
NCT06703658Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of elecoglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs). Started Nov 2024; status: completed.
02
Drugs
elecoglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06703658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703658.